Feed Top Reports Pricing

⌘K

17:18:57·58d

SECFiling

SEC Form 10-K filed by Arvinas Inc.

ARVN· Arvinas Inc.

Health Care

Full content unavailable. See the original source below.

Original source

Companies

ARVN
Arvinas Inc.
Health Care

Recent analyst ratings

Jan 6UpdateCitigroup$15.00
Oct 15UpdateGoldman$6.00
Sep 24UpdateBofA Securities$10.00
Sep 17UpdateBarclays$16.00
Jun 2UpdateLeerink Partners$9.00
May 5UpdateTruist$11.00

Related

SEC28d
Amendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.
INSIDER35d
SEC Form 4 filed by Berkowitz Noah
SEC36d
Arvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
PR36d
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days
SEC37d
SEC Form 144 filed by Arvinas Inc.
INSIDER42d
Amendment: President and CEO Teel Randy was granted 147,179 shares, increasing direct ownership by 98% to 296,875 units (SEC Form 4)
PR43d
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
INSIDER45d
Director Morrison Briggs bought $268,070 worth of shares (20,000 units at $13.40), increasing direct ownership by 26% to 96,021 units (SEC Form 4)

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022